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Progression of overt nephropathy in non-insulin-dependent diabetes.
The detection of overt albuminuria (> 300 mg/g creatinine) in the absence
of azotemia was used to diagnose early nephropathy in 34 Pima Indians
with NIDDM of 16 1 years duration. Differential solute clearances were
performed serially to define the course of the glomerular injury over 48
months. At baseline, the GFR (107 5 mI/mm), filtration fraction and
sieving coefficients of relatively permeant dextrans (< 52 A) were all
depressed below corresponding values in 20 normoalbuminuric Pima
Indians with a similar duration of NIDDM. Over the ensuing 48 months
the GFR (—34%) and filtration fraction (—13%) in the nephropathic
patients declined further. The sieving coefficients of large, nearly imper-
meant dextrans (> 56 A radius) increased selectively and fractional
clearances of albumin and IgG increased correspondingly by > 10-fold.
Analysis of the findings with pore theory revealed: (1) a progressive
decline in pore density and the ultrafiltration coefficient (l(); and (2)
broadening of glomerular pore-size distribution that resulted in greater
prominence of large pores (> 70 A radius). We conclude that increasing
loss of intrinsic ultrafiltration capacity is the predominant cause of the
early and progressive decline in GFR that follows the development of
nephropathy in NIDDM. We speculate that progressive impairment of
barrier size-selectivity contributes to but does not fully account for the
increasingly heavy proteinuria that is observed early in the course of this
disorder.
Between 30 and 45% of patients with insulin-dependent diabe-
tes mellitus (IDDM) ultimately develop diabetic nephropathy.
This distinctive renal injury is ushered in by a decade or more of
glomerular hyperfiltration followed by a progressive increase in
the rate of urinary albumin excretion. Initially, the albuminuria
spans a modest range (30 to 300 mg124 hr) quantifiable only with
sensitive immunochemical techniques, and referred to as "mi-
croalbuminuria". Because microalbuminuria has been associated
with a rapid rate of glomerular filtration (GFR) and little or no
alteration in glomerular morphology, it has been referred to as a
stage of incipient nephropathy [1]. Only when albuminuria in-
creases into a range measurable by dipstick (> 300 mg/24 hr) and
referred to as "macroalbuminuria", has a progressive decline in
the GFR and unequivocal histopathological evidence of diffuse
and/or nodular glomeruloscierosis been observed. By convention
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therefore, the development of macroalbuminuria has been used to
define the onset of overt diabetic nephropathy [1]. The latter
appears to advance irrevocably in most affected patients and leads
eventually to end-stage renal failure.
The natural history of nephropathy in patients with non-insulin-
dependent diabetes mellitus (NIDDM) has been more difficult to
characterize than in IDDM. This is particularly true of Caucasians
in whom the onset of NIDDM is difficult to pinpoint and occurs at
an advanced age [2, 3]. The confounding factors include an effect
of aging per se to lower the GFR [4], a high frequency of
co-existent renal disease unrelated to diabetes beyond the age of
50 years [5—7], and a high mortality rate from cardiovascular
disease [8—10]. The latter phenomenon limits the full expression
of the natural history of diabetic nephropathy, with the result that
only 3 to 8% of such patients have been observed to progress
eventually to end-stage renal failure [10].
To circumvent the confounding influence of advanced age on
glomerular function in NIDDM, we conducted a study of the
Pima Indians of the Gila River Indian Community of Arizona.
They have an extraordinarily high incidence rate of NIDDM,
which peaks between the third and fifth decades [11]. Judged by
initial hyperfiltration [12], a high prevalence of micro- and mac-
roalbuminuria [13, 14], histopathological evidence of intercapil-
lary glomerulosclerosis [15], and a high incidence of progressive
renal failure [16], the nephropathy associated with NIDDM in this
population appears to be similar to that observed in IDDM. The
purpose of the present study was to evaluate the course of overt
diabetic nephropathy in this population. To do this we identified
non-azotemic subjects with macroalbuminuria and performed
serial studies of glomerular function over a 48 month interval.
Methods
Subject selection
The Gila River Indian Community and the nearby community
of Ak-chin are inhabited primarily by Pima and the closely
related, Tohono O'odham Indians. Those between the ages of 18
and 60 years, whose heritage was at least 50% Pima, Tohono
O'odham, or a mixture of these two tribes, and who had NIDDM
of  5 years duration were potential candidates for this study.
One hundred eighty-six of these individuals submitted urine
specimens on three occasions, each separated by at least seven
days. The urine was assayed for albumin and expressed as an
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Table 1. Clinical features at the baseline examination
Normoalbuminuria Macroalbuminuria
Men, Women 8, 12 18, 16
Age years 44 2 47 1
Duration of diabetes years 13 1 16 1'
Weight kg
BMI kg/rn2
93 6
34.2 1.9
89 3
31.7 1.1
Systolic BP mm Hg 121 4 134 3
Diastolic BP mm Hg 74 2 86 2
Fasting glucose mg/dl 228 16 240 12
Hemoglobin A1 % 11.4 0.6 12.2 0.3
Serum creatinine rng/dl 0.69 0.02 0.89 0.04
a P < 0.05 vs. normoalbuminuria
albumin-to-creatinine concentration ratio (A/Cr ratio). Thirty-
four subjects with a ratio above 300 mg/g in at least two of the
three urine specimens were judged to have macroalbuminuria,
and hence overt diabetic nephropathy. Each agreed to participate
in a study of glomerular function. Twenty individuals with long-
standing NIDDM and a normal A/Cr ratio (< 30 mg/g) on all
three screening examinations volunteered to serve as controls.
Some clinical features of each group are summarized in Table
1. The nephropathic group had a higher proportion of males than
the normoalbuminric controls. Age did not differ between the two
groups, but the duration of NIDDM was slightly shorter in the
control than the nephropathic group, 13 1 versus 16 1 years,
respectively. Judged by body mass index, the degree of obesity was
similar, as was the level of chronic glycemia (Hemoglobin A1)
upon entry into the study (Table 1). Two control subjects and 15
nephropathic subjects were receiving insulin therapy at the time of
study. Approximately one-half of the members of each group were
taking an oral hypoglycemic agent. Nephropathic subjects differed
from controls in that arterial blood pressure and the serum
creatinine level were higher, albeit still within the normal range
(Table 1).
Study protocol
Cross-sectional studies. Each subject consented to be studied
according to a protocol that had been approved by the review
boards of all participating institutions, namely Stanford Univer-
sity, California, The Cleveland Clinic, Ohio, the National Institute
of Diabetes and Digestive and Kidney Diseases, Maryland, and
the Gila River Indian Community Tribal Council, Arizona.
Subjects were admitted to either the Clinical Research Center
in the Phoenix Indian Medical Center or to an especially equipped
room of the Hu Hu Kam Memorial Hospital in Sacaton, Arizona
for the performance of differential solute clearances. Blood
pressure was determined in the sitting position and mean arterial
pressure (MAP) calculated as the diastolic pressure plus one-third
of the pulse pressure. An indwelling plastic cannula was then
inserted into the antecubital vein of each arm, one for collecting
blood samples and the other for infusing clearance markers.
Serum albumin, immunoglobulin G (IgG) and creatinine concen-
trations were assayed, and the oncotic pressure of plasma was
determined. After the bladder was emptied by spontaneous
voiding, urine was examined to determine the A/Cr and IgG-to-
creatinine (IgG/Cr) ratios. A diuresis was next initiated with an
oral water load of either 10 mi/kg or 1500 ml in the case of
subjects weighing > 150 kg. Clearance markers were infused
beginning with a loading dose of 30% iothalamate (300 mg plus 3
mg/kg for each kg above 100 kg), 20% para-aminohippuric acid
(PAH, 16 mg/kg) and 10% dextran 40 (150 mg/kg). Each clear-
ance marker was then delivered by an infusion pump to maintain
iothalamate and PAR plasma concentrations constant at 1.5 and
2.0 mg/dl, respectively [12]. Dextran 40 was infused at half the rate
of iothalamate. After a 60-minute equilibration period, the blad-
der was again emptied by voiding, and four carefully timed urine
collections were made at approximately 20 minute intervals.
Blood was drawn to bracket each urine collection. To prevent the
formation of PAH-glucose adducts in urine, 4 ml of each urine
collection was promptly alkalinized by addition of 30 1il of 4 M
NaOH [17, 18],
The average urinary clearance of iothalamate was equated with
the GFR. In light of earlier demonstrations in non-azotemic
diabetic subjects of normal renal PAH extraction, the correspond-
ing clearance of PAR was used as a measure of renocortical
plasma flow rate (RPF) [19, 20]. Fractional clearances of dextran
macromolecules in the 32 to 60 A radius interval were calculated
for the second or third timed collection period by dividing the
clearance of each dextran by that of iothalamate. Fractional
clearances of the endogenous proteins, albumin and IgG were
determined simultaneously.
Longitudinal studies. The nephropathic group underwent longi-
tudinal study for a period of 48 months. Serial clearances of
iothalamate, PAR and endogenous proteins were repeated at six
month intervals. Dextran sieving measurements were performed
at baseline and after 48 months, with one exception. The excep-
tion was a subject who advanced to end-stage renal failure after 37
months. In this case the exit study of dextran sieving was per-
formed after 32 months of follow-up. Four patients were lost to
follow-up; the remaining 30 members of the nephropathic cohort
completed the 48 month study. The baseline renal function of the
four subjects who dropped out did not differ significantly from
those who completed follow-up. The primary physicians of the
participating nephropathic patients prescribed angiotensin con-
verting enzyme inhibitors (ACEi) for 13 subjects during the
course of the study. Of these eight reported taking the ACEi at
only one examination, three at two examinations and two at four
examinations. Consequently, six subjects (20%) were on ACEi at
some time during the first year, one (3%) during the second year,
three (10%) during the third year, and eight (27%) during the
fourth and last year of the study. The relatively widespread use of
ACEi during the last study year coincided with the publication of
two reports which indicated a renoprotective effect of this agent in
patients with diabetic nephropathy [21, 22].
Laboratory procedures
The concentrations of albumin and IgG in serum of all subjects
and in the urine of nephropathic subjects were determined by
immunoprecipitation using a semi-automated nephelometer
(Behring Diagnostics, Somerville, NJ, USA). The concentrations
of albumin and IgG in the urine of control subjects were at or
below the lowest standard of the nephelometric assay, and were
determined instead with a sensitive enzyme-linked immunosor-
bent assay [23]. All samples were stored at —70°C until the day of
assay, which was performed within 30 days of the collection of the
sample.
A high pressure liquid chromatography system with a sensitive
ultraviolet light detector was used to assay iothalamate and PAH
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at 236 nm (Instrumentation Shimadzu #6A, Kyoto, Japan).
Ultrafiltrates of plasma and diluted urine were injected onto a
reverse phase column (#C18, 5 s Ultrasphere, Beckman, San
Ramon, CA, USA). The mobile phase was 3.5% acetonitrile in 10
mM triethylamine at a pH of 3.5, and the flow rate was 1.0 ml/min.
lothalamate and PAH concentrations were determined from the
peak area of each solute, corresponding to column retention times
of 14 and 10 minutes, respectively [121.
Separation of dextran 40 in urine and protein-free filtrates of
plasma into narrow fractions was achieved by high pressure liquid
chromatography using two columns in series (Ultrahydrogel 250
and 500; Waters Division, Millipore Corp., Milford, MA, USA).
The columns were calibrated with four narrowly-dispersed dex-
tran fractions of known molecular weight (9.9, 25.6, 53.5 and 72.6
kD, respectively), provided by Dr. K. Granath of Pharmacia Fine
Chemicals (Uppsala, Sweden). Dextran concentration was mea-
sured using a refractive index detector (Instrumentation Shi-
madzu #RID-6A). An integrator (Spectraphysics #4270, San
Jose, CA, USA) was used to divide the chromatogram into four
slices per minute during the 40 minute run. The integrated area of
each slice was equated with the dextran concentration at the
corresponding retention time. Molecular weight (MW) was cal-
culated from its relationship with retention time and molecular
radius (r) was then computed from molecular weight using the
equation:
= 0.33 x (MWj°463
The interassay coefficient of variation for fractional dextran
clearance at each size interval varied between 3.3 and 10.5%.
Oncotic pressure of plasma was determined by membrane
osmometry using a Wescor 4400 colloid osmometer (Wescor Inc.,
Logan, UT, USA), and the concentration of creatinine by a
rate-dependent modification of the Jaffe reaction [24].
Analysis of glomerular membrane-pore structure
To characterize the size-selective properties of the glomerular
barrier, we employed a theoretical model which represents the
glomerular capillary wall as a heteroporous membrane that is
perforated by cylindrical pores with radii which are assumed to
follow a lognormal distribution [25]. The two parameters which
characterize this distribution are the mean pore radius (u) and the
standard deviation about the mean (5) of the lognormal pore size
distribution. This theoretical model also estimates volume flows
and fluxes and the dextran concentration along the length of the
glomerular capillaries, thereby permitting computation of an
ultrafiltration coefficient (l(f), which is the product of effective
hydraulic permeability and total glomerular capillary surface area
in the two human kidneys. An additional membrane parameter
that can be derived from Kf and pore radius is the ratio of effective
pore area-to-length (S'/l),which is closely related to the apparent
number of glomerular pores in the two kidneys. Provided that
pore length (1) does not differ between the two groups, changes in
S'Il would be predicted to be nearly proportional to changes in the
total number of pores in the membrane (pore density) [26].
To evaluate the influence of GFR determinants on convective
and diffusive transmembrane transport, the model requires knowl-
edge of GFR, RPF, ITA and the transcapillary hydraulic pressure
difference, P [25, 26]. The latter quantity cannot be directly
measured in humans, but has been estimated by two different
indirect methods to range from 35 to 40 mm Hg in healthy
subjects [27, 281. Micropuncture determinations in diabetic rats
have revealed moderate hyperglycemia to be associated with a
selective or disproportionate fall in preglomerular (afferent)
segmental vascular resistance. This permits a greater fraction of
arterial pressure to be transmitted into glomerular capillaries,
thereby increasing P [29, 30]. Based on these findings, we infer
that zP is unlikely to have been below the normal range in the
diabetic subjects of the present study, and arbitrarily assigned a
value of zP = 40 mm Hg to each subject for the purpose of
calculating membrane parameters.
Statistical analysis
Results are expressed as the mean SE, except for variables
with highly skewed distributions, such as the urinary protein
excretion ratios and fractional clearances, which are expressed as
medians and ranges. All P values are for two-sided tests, and
results are deemed significant if P < 0.05. Age and sex were
included as covariates in these analyses. Urinary AJCr and IgG/Cr
ratios and the corresponding fractional clearances of each protein
were analyzed after a logarithmic transformation. Paired tests
(t-tests or signed rank) were used to evaluate differences from
baseline at the 48 month examination in nephropathic patients.
Differences between groups among fractional clearances of
discrete dextrans at 2 A radius intervals were first examined by
t-tests with no adjustment for multiple comparisons. Differences
among the entire fractional dextran clearance profiles were then
analyzed by deriving membrane parameters from the theoretical
model. The membrane parameters of the nephropathic group
were then compared to those of controls using a nonparametric
test (Kruskal-Wallis). A paired analysis was used to compare
membrane parameters after 48 months in the nephropathic group
to corresponding values at baseline.
Not all nephropathic patients attended the scheduled six
monthly studies regularly. To assess serial changes in the quanti-
ties of interest, we used two statistical methods which take missing
values into account. Linear regression analysis was used to derive
a slope from the serial determinations of GFR and the fractional
clearances of albumin and IgG [31]. We also used a mixed-effect
model which combines spline fitting for each serially measured
parameter with a random effect of the follow-up time [31, 32].
Results
Cross sectional observations
Renal protein handling and filtration dynamics upon entry into
the study are summarized in Table 2. Because of the higher
proportion of males in the nephropathic than the control group,
the glomerular flows (GFR and RPF) are expressed per 1.73 m2
of body surface area, so as to take gender differences in body size
into account. The mean GFR in the control group was higher by
23 ml/min/1.73 m2 than the corresponding value that we have
reported previously [12] for non-diabetic Pima Indians (110 4).
This finding suggests that long-standing NIDDM in the absence of
detectable nephropathy is associated with hyperfiltration [12].
Mean RPF in the control group was also elevated, in this case, by
112 ml/min/1.73 m2 above the corresponding value (560 25)
observed in non-diabetic Pima Indians [12]. In riephropathic
patients as well, the RPF was elevated, but the GFR had "fallen
back" into the normal non-diabetic range, and was significantly
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Normoalbuminuria Macroalbuminuria
Fractional clearance of
albumin X103
0.001 (0.0001—0.004) 0.148 (0.030—6.73)"
Fractional clearance of
IgG X103
GFR ,nl/mjn/1.73 m2
0.002 (0.0002—0.006)
133 7
0.050 (0.012—2.68)"
107 5b
RPF mi/mm/i. 73 m2 672 34 658 28
Filtration fraction 0.20 0.009 0.17 0.006"
A mm Hg
MAPmmHg
Estimated K1
21.6 0.5
90±3
9.8 (7.511.6)
21.0 0.4
102±2"
6.6 (6088)b
mi/mm mm Hga
lower than the corresponding value in the non-nephropathic
control subjects: 107 5 versus 133 7 ml/min/1.73 m2,
respectively. The selective reduction in GFR in the nephropathic
group resulted in a depressed filtration fraction, averaging 0.17
versus 0.20 in the control group (Table 2). Whereas A was
similar in the two groups, the nephropathic group exhibited
significant arterial hypertension (Table 2). Thus, macroalbumin-
uria in non-azotemic diabetic Pima Indians was accompanied by a
fall in GFR into the normal range, a depressed filtration fraction,
and the development of hypertension.
The A/Cr ratio and fractional albumin clearance in the nephro-
pathic group were elevated above control values by two to three
orders of magnitude (Table 2). The corresponding IgG/Cr ratio
and fractional IgG clearance were also markedly elevated, albeit
slightly less than in proportion to corresponding values for
albumin (Table 2). Of note, the fractional clearances of IgG and
albumin in the nephropathic group were strongly related (r =
0.99), suggesting that the glomerular permeability to each protein
increased in parallel (Fig. 1).
The mean dextran sieving profiles for each group are illustrated
in Figure 2. In the nephropathic subjects, dextran sieving coeffi-
cients at the low radius end of the sieving profile (32 to 50 A
32 34 36 38 40 42 44 46 48 50 52 54 56 58 60
Dextran radius, A
Fig. 2. Dextran sieving curves in macroalbuminuric subjects at baseline
(dashed) vs. normoalbuminuric controls (solid) (*P < 0.05 vs. control).
interval) were significantly depressed below corresponding values
in the control subjects. The sieving coefficients for large, nearly
impermeant dextrans (radii 52 to 60 A) did not differ between the
two groups (Fig. 2).
The computed pore-size distribution for each group is illus-
trated in Figure 3. The median pore radius is smaller (43.8 vs.
46.1 A, P < 0.01) and the standard deviation of the distribution
(S) is larger (1.204 vs. 1.183, P < 0.05) in the nephropathic
compared to the control group. The larger value for S reflects a
broader distribution of pore size. As shown in Figure 3, the
predominant change in nephropathic subjects is a relative in-
crease in pores of smaller radius. However, a minor trend towards
larger pores >70 A radius can also be discerned at the upper end
of the distribution (Fig. 3), and could have contributed to the
elevated fractional clearances of albumin and IgG in the nephro-
pathic subjects. In addition to the altered pore-size distribution,
the model also reveals a loss of ultrafiltration capacity by glomer-
nh of nephropathic subjects. Median values for K1 in the latter
were depressed below control values: 6.6 versus 9.8 ml/(mm mm
Hg), respectively (P < 0.05, Table 2). Corresponding values for
S'/l were 208 versus 283 km, respectively (P = NS).
Longitudinal observations
As stated previously, 30 members of the original cohort of 34
subjects completed a re-evaluation of glomerular function after 48
months. They participated irregularly in the intervening six
monthly studies, however, with the result that the group, as a
Table 2. Glomerular function at the baseline examination
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30 40 50 60
Pore radius, A
Fig. 3. Lognormal distribution of pore radii in macroalbuminuric subjects at
baseline (dashed) and after 48 months (solid) vs. normoalbuminuric controls
(finely dotted).
whole, underwent an average of six serial clearance studies (range
3 to 9). Two approaches which take missing data into account
were used to estimate the course of GFR over the period of
observation (see Statistical methods). The mixed effect model
revealed a significant decline in GFR below baseline at all time
points from 12 months onwards (P < 0.05) and a trend towards a
progressively greater decline in GFR with the passage of time
(Fig. 4). As described in the Methods section, ACEi therapy was
initiated in 13 subjects during the course of our observations, and
eight other subjects received therapy with j3 blockers and/or
diuretics. As a result, serial determinations of blood pressure did
not differ significantly from baseline throughout the 48 months of
follow-up (Fig. 5). Nevertheless, the average decline below base-
line for GFR at the end of follow-up was by 42 mI/mm.
The course of GFR was also evaluated by using linear regres-
sion analysis to derive a GFR slope from the serial determinations
[31]. Linear regression was also used to derive a slope for the
natural log of the corresponding fractional protein clearances. As
shown in Figure 6, most subjects exhibited a negative slope for
GFR, and a positive slope for fractional protein clearance. The
inverse relationship was highly significant for the slope of GFR
versus that of both fractional albumin clearance (r =
—0.69, P <
0.001, not shown) and fractional lgG clearance (r =
—0.74, P <
0.001, Fig. 6). Thus, increasing damage to glomerular capillary
walls in these nephropathic subjects was characterized by a trend
towards declining GFR and increasing permeability to albumin
and lgG.
comletin the 48 month study were
compared to corresponding findings at baseline. Neither weight,
BMI nor fasting glucose at the 48 month examination differed
significantly from baseline. On average, however, glomerular
dysfunction was substantially more marked at the 48 month than
at the baseline examination. The A/Cr and IgG/Cr ratios in-
creased by —threefold, and the corresponding fractional clear-
ances of each protein were enhanced by an order of magnitude
(Table 3). Mean GFR declined significantly by 35% from 108 6
Months
N= (30) (23) (27) (28) (26) (28) (26) (21) (30)
\. S. Serial detenninations of systolic and diastolic blood pressures in the
nephropathic group. The number of observations at each interval is in
parentheses below the x-axis. None of the serial determinations differ
significantly from baseline.
to 71 9 ml/min/1 .73 m2. Mean RPF also declined significantly,
but less than in proportion to the GFR. As a result the filtration
fraction was significantly lower at the 48 month examination than
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.
U • U
—0.02 0 0.02 0.04 0.06 0.08 0.1 0.12 0.14
Slope of In, fractional lgG clearance x105
Fig. 6. Relationship between the GFR slope (mi/mm/month) and the corre-
sponding slope of the natural log of fractional IgG clearance in the
nephropathic group. The dashed line is the regression line (r —0.74, P <
0.001).
Baseline 48 Months
Albumin-to-creatinine 1036 (333—8944) 2824 (17O_13,000)b
ratio mg/ga
IgG-to-creatinine ratio 131 (25—1332) 434 (26—3567)'
mgig4
Fractional clearance of
albumin
0.148 (0.030—6.73) 1.51 (0.032—56.6)
Fractional clearance of
IgU xlo—sa
0.050 (0.012—2.68) 0.635 (O.016_327)b
GFR ml/min/1.73 m2 108 6 71 9'
RPF mi/mini]. 73 m2 666 30 495 43'
Filtration fraction 0.16 0.006 0.14 0•007b
A mm Hg 21.1 0.4 20.5 0.6
MAP mm Hg 102±2 103±2
Estimated Kf 7.1 (6.0—8.9) 3.8 (2.3—6.7)'
mlimin mm Hg
at baseline (Table 3). Neither ITA nor MAP changed significantly
between the two examinations.
The increase in the urinary excretion and fractional clearance of
protein after 48 months was accompanied by an alteration in the
dextran sieving profile. A non-significant trend towards restricted
transglomerular passage was evident for dextran molecules of
< 40 A radius. In contrast, the passage of larger molecules was
enhanced, and the sieving coefficients for dextrans of 58 and 60 A
radius were significantly elevated above corresponding baseline
values at the 48 month examination (Fig. 7). We used the
observed values for dextran sieving coefficients, GFR, RPF, and
A and assumed isP = 40 mm Hg to compute the prevailing
membrane parameters. The median pore density declined signif-
icantly from 212 at baseline to 122 km at the 48 month examina-
tion (P < 0.05). A parallel decline by —50% was computed for
median iç (Table 3). There was also a further alteration in
pore-size distribution which is illustrated in Figure 3 to permit
comparison to baseline. The peak radius (u) was shifted to yet a
smaller size (42.4 vs. 43.8 A), and the distribution of pores (S) was
broadened (S 1.219 vs. 1.204, P < 0.05). The broadened
pore-size distribution at 48 months included pores of larger as
well as smaller radius than were evident at baseline. Of note, the
fraction of filtrate that permeated pores > 70 A radius at 48
months in the nephrotic subjects was twofold larger than the
corresponding fraction in normoalbuminuric controls (Fig. 3).
Thus, according to this analysis, the declining GFR in these
nephropathic patients can be attributed to a progressive loss of
intrinsic ultrafiltration capacity. A simultaneous broadening of
glomerular pore-size distribution to include a greater fraction of
pores of above 70 A radius could have contributed to the
increasingly heavy proteinuria observed over time (Fig. 3).
Discussion
We have recently reported that hyperfiltration is evident soon
after the onset of NIDDM in the Pima Indians [12]. The finding
in the present study that long-standing NIDDM in the normoalbu-
minuric subjects of the control group continues to be associated
with an elevated GFR is of considerable interest. It is reminiscent
of IDDM [1] and suggests that hyperfiltration is a non-specific
characteristic of the diabetic state, and one that is independent of
the etiology of the diabetes [3]. Our finding that the baseline GFR
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Fig. 7. Dextran sieving cuives in macroalbuminuric subjects at baseline
(solid) and after 48 months (dashed) (*P < 0.05 vs. baseline).
Table 3. Glomerular function in nephropathic subjects at baseline and
after 48 months
a Median (range)bp < 0.05 vs. baseline value
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in the nephropathic group was not similarly elevated suggests that
the development of macroalbuminuria coincided with an alter-
ation in one or more of the determinants of GFR.
Neither changes in RPF nor in TA can be invoked to explain an
initial value for GFR that was lower in nephropathic subjects than
controls (Table 2). To the contrary, a trend to lower A and a
significant reduction of the filtration fraction must have lowered
the intraluminal glomerular capillary oncotic pressure in the
nephropathic group relative to control values [33]. Further, the
finding that arterial pressure was 12 mm Hg higher in the
nephropathic than in the control group makes it unlikely that P
could have been depressed [29, 30]. By exclusion, we infer that the
lower GFR and filtration fraction observed in the nephropathic
subjects is most likely to reflect a decline in the glomerular
ultrafiltration coefficient, KI [33].
That Kf was indeed lower in the nephropathic subjects is
supported by the finding that the passage of dextrans of < 50 A
radius was restricted [26]. Application of a hydrodynamic theory
of solute transport through a heteroporous membrane attributed
this phenomenon to two alterations in intrinsic membrane prop-
erties. One was a reduction of mean pore radius. The other was a
33% depression of Kf (Table 2). A third membrane parameter,
S'Il, was derived from Kf and pore radius [26]. It represents the
ratio of effective area-to-pore length and was numerically reduced
by 27%. Provided that pore length did not differ between control
and nephropathic subjects, this implies that the total number of
glomerular pores was lower in the latter group. Thus, whether
expressed as an ultrafiltration coefficient or as pore density, the
restricted dextran sieving in nephropathic patients points to a loss
of intrinsic ultrafiltration capacity by glomerular capillary walls.
The K in the present study has been defined as the product of
hydraulic permeability and the total surface area available for
filtration in all glomeruli in the kidneys of each subject. Morpho-
metric analyses of glomeruli obtained by biopsy from patients with
early nephropathy complicating IDDM have revealed a reduction
in both of the foregoing terms. Global sclerosis of a substantial
fraction of glomeruli in such biopsies has attested to one obvious
mechanism by which filtration surface is curtailed [34—36]. An-
other reported finding that would further limit filtration surface
area is an impingement on the peripheral glomerular capillaries of
patent glomeruli by an expanding mesangium [34—37]. The gb-
merular basement membrane and the interpodocytic slit dia-
phragms have been shown to be the major determinants of
hydraulic permeability, with each structure accounting for approx-
imately 50% of resistance to transcapillary water flow [38].
Morphometric studies have shown the basement membrane to be
invariably thickened in early diabetic nephropathy [34—37]. Sim-
ilarly epithelial foot processes have been shown to be broadened,
leading to a reduction in the frequency of filtration slits and by
extension, of the associated slit diaphragms [34, 39]. Together
these latter two alterations are predicted to lengthen the filtration
pathway, and hence to lower hydraulic permeability. Preliminary
study of glomerular morphometry in the nephropathic subjects of
the present study has revealed the same constellation of structural
alterations as reported in IDDM [40]. Thus, it seems likely that a
simultaneous reduction in both filtration surface area and hydrau-
lic permeability provide the basis for the depressed K that we
compute to have prevailed at the onset of the nephropathy in our
patients with NIDDM. Given constancy of arterial pressure and a
trend to lower A' we infer that increasing derangement of
glomerular structure and ultrafiltration capacity is likely also to
have accounted for the progressive decline in the GFR and
filtration fraction that we observed during the 48 months of
follow-up (Table 3).
Our theoretical analysis of the nephropathic dextran sieving
profile suggests a modest impairment of barrier size-selectivity
[41]. This is attested to by the sieving behavior of glomeruli
towards the largest dextran molecules. Whereas the sieving coef-
ficients for smaller dextrans were depressed relative to values in
normoalbuminuric control subjects with NIDDM, the glomerular
capillary walls of nephropathic subjects at baseline exhibited a
selective failure to restrict the passage of large, nearly impermeant
dextrans of > 50 A radius (Fig. 2). This was followed after 48
months by a selective enhancement of passage of the largest
dextran molecules (Fig. 7). This serial change in dextran sieving is
interpreted to reflect a progressive broadening of pore-size dis-
tribution in nephropathic subjects. Whereas the shift in pore-size
distribution was mostly towards pores of smaller radius, there was
also a trend towards increasing prominence of large pores of> 70
A radius (Fig. 3). Because of a configurational difference from
proteins, dextran sieving coefficients overestimate the radius of
pores encountered by proteins as they cross the gbomerular barrier
[42, 43]. Nevertheless, pores that present a radius of> 70 A radius
to permeating dextrans are likely to be permeable also to albumin
(radius = 36 A) and IgG (radius = 55 A), and could contribute to
the enhanced transglomerular passage of each protein that was
observed. However, the increment in large pores that are poten-
tially protein-permeable appears to be too small to account for the
large disparity in protein clearance between the nephropathic and
control subjects of the present study.
In addition to restricting circulating proteins on the basis of
their size, the gbomerular capillary wall also behaves as a nega-
tively-charged electrostatic barrier [44, 45]. Studies in animals and
humans with diabetic nephropathy have demonstrated a depletion
of the fixed, negatively-charged sites within the glomerular capil-
lary wall that normally impose this charge-selectivity [44—48]. It is
therefore conceivable that a similar depletion in our nephropathic
subjects contributed to the observed level of albuminuria. An
isolated loss of barrier charge-selectivity cannot be invoked to
explain the observed level of immunoglobulinuria, however. Not
only are IgG molecules considerably larger than albumin mole-
cules, but they also bear a predominantly positive charge [23].
Thus, impairment of size- rather than charge-selectivity appears
to be required to explain the heavy and increasing immunoglobu-
linuria in the nephropathic subjects of the present study. To the
extent that impaired charge-selectivity might have contributed to
the observed level of albuminuria, the strong relationship between
the fractional clearances of albumin and IgG in the nephropathic
subjects (Fig. 1) suggests that the charge- and size-selective
properties of the glomerular barrier must have deteriorated in
parallel. This relationship is strongly reminiscent of the alteration
in barrier function observed in the nephropathy of IDDM, and
suggests a common mechanism of proteinuria in each form of
diabetic nephropathy [34, 41, 49].
A final similarity between the nephropathy of these subjects
with NIDDM and that reported for patients with IDDM is a
downhill course characterized by a progressive impairment of
ultrafiltration capacity and barrier function over time [34, 50]. On
the other hand, an intriguing difference is our observation in the
nephropathy of NIDDM of a trend for GFR to decline more
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rapidly than is usually reported for the nephropathy of LDDM.
Despite the maintenance of arterial pressure within a nearly
normal range throughout the study (Fig. 6) and the administration
of a converting enzyme inhibitor to a subset of the patients, the
GFR declined by 37 mI/mm over 48 months, on average. The
approximate annual decline rate of 9 ml!min/year is two to three
times more rapid than has been reported under similar conditions
for the nephropathy of IDDM [51, 521. This raises the possibility
that Pima Indians with NIDDM might be susceptible to other
factors that accelerate the progression of nephropathy. Less
efficient control of hyperglycemia could be one such factor [53].
Another is the finding that Pima Indians, whether diabetic or
non-diabetic, have glomeruli which are at least twofold larger than
in Caucasian populations [54]. Further study will be required to
confirm that the downhill course of nephropathy in Pima Indians
with NIDDM is indeed more rapid than that seen in IDDM, and
to elucidate the possible factors that might contribute to such
rapid progression.
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